{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T06:10:41Z","timestamp":1791526241760,"version":"4.3.4"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T00:00:00Z","timestamp":1660176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["por-journal.com"],"crossmark-restriction":true},"short-container-title":["Pathol. Oncol. Res."],"abstract":"<jats:p>Immunohistochemical markers are associated with treatment outcome in adults with classical Hodgkin Lymphoma (cHL). Studies in children are scarce and inconsistent. We investigated in 67 children with cHL, whether the expression of CD15, CD30, PAX5, PD-1, PD-L1, CD68, CD163 and TARC at diagnosis is associated with disease free survival (DFS) and with interim remission status. Low CD15 and low TARC expression were associated with relapsed disease. Low expression of PD-L1 was associated with complete remission at interim PET-scan. Our data suggest a difference between pediatric and adult cHL. This underlines the importance of future research into specific prognostic factors in pediatric cHL, indispensable for improvement of treatment in this population.<\/jats:p>","DOI":"10.3389\/pore.2022.1610482","type":"journal-article","created":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T04:11:27Z","timestamp":1660191087000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["The Prognostic Value of Eight Immunohistochemical Markers Expressed in the Tumor Microenvironment and on Hodgkin Reed-Sternberg Cells in Pediatric Patients With Classical Hodgkin Lymphoma"],"prefix":"10.3389","volume":"28","author":[{"given":"Eline A. M.","family":"Zijtregtop","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilse","family":"Tromp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana","family":"Dandis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian M.","family":"Zwaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"King H.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike A. G.","family":"Meyer-Wentrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Auke","family":"Beishuizen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/path.2711","article-title":"The Classical Hodgkin's Lymphoma Microenvironment and its Role in Promoting Tumour Growth and Immune Escape","volume":"221","author":"Aldinucci","year":"2010","journal-title":"J Pathol"},{"key":"B2","article-title":"Hodgkin\u2019s Lymphoma","volume-title":"Harrison's Principles of Internal Medicine","author":"Jacobson","year":"2018"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e2014053","DOI":"10.4084\/mjhid.2014.053","article-title":"Prognostic Factors in Hodgkin Lymphoma","volume":"6","author":"Cuccaro","year":"2014","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12916-016-0711-6","article-title":"Meta-Analysis of the Prognostic and Clinical Value of Tumor-Associated Macrophages in Adult Classical Hodgkin Lymphoma","volume":"14","author":"Guo","year":"2016","journal-title":"BMC Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1182\/bloodadvances.2017006346","article-title":"High Proportions of PD-1+ and PD-L1+ Leukocytes in Classical Hodgkin Lymphoma Microenvironment are Associated with Inferior Outcome","volume":"1","author":"Hollander","year":"2017","journal-title":"Blood Adv"},{"key":"B6","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/pai.0000000000000200","article-title":"Expression of TIA1 and PAX5 in Classical Hodgkin Lymphoma at Initial Diagnosis May Predict Clinical Outcome","volume":"24","author":"Nguyen","year":"2016","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/nejmoa0905680","article-title":"Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma","volume":"362","author":"Steidl","year":"2010","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3762","DOI":"10.1158\/1078-0432.ccr-12-0129","article-title":"Tumor-Associated Macrophages in Pediatric Classical Hodgkin Lymphoma: Association with Epstein-Barr Virus, Lymphocyte Subsets, and Prognostic Impact","volume":"18","author":"Barros","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/pbc.21204","article-title":"Proliferative Index and CD15 Expression in Pediatric Classical Hodgkin Lymphoma","volume":"50","author":"Dinand","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1016\/j.ejca.2013.05.024","article-title":"The Prognostic Impact of Tumour-Associated Macrophages and Reed-Sternberg Cells in Paediatric Hodgkin Lymphoma","volume":"49","author":"Gupta","year":"2013","journal-title":"Eur J Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1182\/blood-2018-08-870915","article-title":"Serum Levels of TARC, MDC, IL-10, and Soluble CD163 in Hodgkin Lymphoma: A SWOG S0816 Correlative Study","volume":"133","author":"Hsi","year":"2019","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1007\/s00262-020-02787-2","article-title":"Epstein-Barr Virus Recruits PDL1-Positive Cells at the Microenvironment in Pediatric Hodgkin Lymphoma","volume":"70","author":"Jimenez","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B13","doi-asserted-by":"publisher","first-page":"130","DOI":"10.5146\/tjpath.2020.01514","article-title":"Relationship of Tumor-Associated Macrophage Population Detected by CD68 PG-M1, CD68 KP1, and CD163 with Latent EBV Infection and Prognosis in Classical Hodgkin Lymphoma","volume":"37","author":"Mavili","year":"2021","journal-title":"Turk Patoloji Derg"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1002\/ijc.27314","article-title":"Tumor Microenvironment Composition in Pediatric Classical Hodgkin Lymphoma Is Modulated by Age and Epstein-Barr Virus Infection","volume":"131","author":"Barros","year":"2012","journal-title":"Int J Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"7604","DOI":"10.1200\/jco.2005.02.6310","article-title":"Epstein-Barr Virus as a Marker of Survival after Hodgkin's Lymphoma: A Population-Based Study","volume":"23","author":"Keegan","year":"2005","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e1311","DOI":"10.1002\/cnr2.1311","article-title":"The Circuitry of the Tumor Microenvironment in Adult and Pediatric Hodgkin Lymphoma: Cellular Composition, Cytokine Profile, EBV, and Exosomes","volume":"4","author":"Nagpal","year":"2021","journal-title":"Cancer Rep (Hoboken)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1200\/jco.2016.66.4482","article-title":"PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1097\/00000478-200107000-00011","article-title":"TARC, a CC Chemokine, Is Frequently Expressed in Classic Hodgkin's Lymphoma but Not in NLP Hodgkin's Lymphoma, T-Cell-Rich B-Cell Lymphoma, and Most Cases of Anaplastic Large Cell Lymphoma","volume":"25","author":"Peh","year":"2001","journal-title":"Am J Surg Pathol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"884","DOI":"10.3390\/cancers13040884","article-title":"Biology and Clinical Applicability of Plasma Thymus and Activation-Regulated Chemokine (TARC) in Classical Hodgkin Lymphoma","volume":"13","author":"Zijtregtop","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.1200\/jco.2013.52.5410","article-title":"Dose-Intensive Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents with Newly Diagnosed Intermediate-Risk Hodgkin Lymphoma: A Report from the Children's Oncology Group Study AHOD0031","volume":"32","author":"Friedman","year":"2014","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/pbc.20031","article-title":"Treatment of Pediatric Hodgkin Disease Avoiding Radiotherapy: Excellent Outcome with the Rotterdam-HD-84-Protocol","volume":"43","author":"Hakvoort-Cammel","year":"2004","journal-title":"Pediatr Blood Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S1470-2045(21)00470-8","article-title":"Response-Adapted Omission of Radiotherapy and Comparison of Consolidation Chemotherapy in Children and Adolescents With Intermediate-Stage and Advanced-Stage Classical Hodgkin Lymphoma (EuroNet-PHL-C1): A Titration Study With an Open-Label, Embedded, Multinational, Non-Inferiority, Randomised Controlled Trial","volume":"23","author":"Mauz-K\u00f6rholz","year":"2022","journal-title":"Lancet Oncol"},{"key":"B23","volume-title":"Second International Inter-group Study for Classical Hodgkin\u2019s Lymphoma in Children and Adolescents","year":"2014"},{"key":"B24","first-page":"1227","article-title":"Expression of Epstein-Barr Virus in Classical Hodgkin's Lymphomas in Brazilian Adult Patients","volume":"86","author":"Vassallo","year":"2001","journal-title":"Haematologica"},{"key":"B25","first-page":"1123","article-title":"Classical Hodgkin's Disease. Clinical Impact of the Immunophenotype","volume":"151","author":"von Wasielewski","year":"1997","journal-title":"Am J Pathol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1002\/eji.200635972","article-title":"IL-4 Induces Expression of TARC\/CCL17 via Two STAT6 Binding Sites","volume":"36","author":"Wirnsberger","year":"2006","journal-title":"Eur J Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1182\/blood-2008-01-133769","article-title":"Vorinostat Inhibits STAT6-Mediated TH2 Cytokine and TARC Production and Induces Cell Death in Hodgkin Lymphoma Cell Lines","volume":"112","author":"Buglio","year":"2008","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/bjh.16514","article-title":"Interim Thymus and Activation Regulated Chemokine versus Interim 18 F\u2010Fluorodeoxyglucose Positron\u2010Emission Tomography in Classical Hodgkin Lymphoma Response Evaluation","volume":"190","author":"Plattel","year":"2020","journal-title":"Br J Haematol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative Analysis Reveals Selective 9p24.1 Amplification, Increased PD-1 Ligand Expression, and Further Induction via JAK2 in Nodular Sclerosing Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1007\/s11899-020-00589-y","article-title":"PD-1\/PD-L1 Pathway and its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas","volume":"15","author":"Xie","year":"2020","journal-title":"Curr Hematol Malig Rep"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1182\/blood-2017-03-770719","article-title":"Topological Analysis Reveals a PD-L1-Associated Microenvironmental Niche for Reed-Sternberg Cells in Hodgkin Lymphoma","volume":"130","author":"Carey","year":"2017","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3322\/caac.21438","article-title":"Hodgkin Lymphoma: A Review and Update on Recent Progress","volume":"68","author":"Shanbhag","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1200\/jco.19.00315","article-title":"Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study","volume":"37","author":"Ramchandren","year":"2019","journal-title":"J Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"3280","DOI":"10.1182\/blood-2012-04-421057","article-title":"Tumor-Associated Macrophages Predict Inferior Outcomes in Classic Hodgkin Lymphoma: A Correlative Study from the E2496 Intergroup Trial","volume":"120","author":"Tan","year":"2012","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/j.1600-0609.2011.01731.x","article-title":"CD68 and CD163 as Prognostic Factors for Korean Patients with Hodgkin Lymphoma","volume":"88","author":"Yoon","year":"2012","journal-title":"Eur J Haematol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e450","DOI":"10.1016\/s2352-3026(18)30153-4","article-title":"Brentuximab Vedotin for Paediatric Relapsed or Refractory Hodgkin's Lymphoma and Anaplastic Large-Cell Lymphoma: A Multicentre, Open-Label, Phase 1\/2 Study","volume":"5","author":"Locatelli","year":"2018","journal-title":"Lancet Haematol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1200\/jco.20.03286","article-title":"Excellent Outcome for Pediatric Patients with High-Risk Hodgkin Lymphoma Treated with Brentuximab Vedotin and Risk-Adapted Residual Node Radiation","volume":"39","author":"Metzger","year":"2021","journal-title":"J Clin Oncol"}],"container-title":["Pathology and Oncology Research"],"original-title":[],"link":[{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2022.1610482\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T04:11:32Z","timestamp":1660191092000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2022.1610482\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,11]]},"references-count":37,"alternative-id":["10.3389\/pore.2022.1610482"],"URL":"https:\/\/doi.org\/10.3389\/pore.2022.1610482","relation":{},"ISSN":["1532-2807"],"issn-type":[{"value":"1532-2807","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,11]]},"article-number":"1610482"}}